UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 286

Sortiert nach

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Clinical pharmacology and therapeutics, 2018-02, Vol.103 (2), p.210-216

2018

Volltextzugriff (PDF)

Pharmacogenomic‐Guided Therapy in Colorectal Cancer

Clinical pharmacology and therapeutics, 2021-09, Vol.110 (3), p.616-625

2021

Volltextzugriff (PDF)

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy

Cancers, 2022-06, Vol.14 (13), p.3207

2022

Volltextzugriff (PDF)

Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity

Cancer research (Chicago, Ill.), 2014-05, Vol.74 (9), p.2545-2554

2014

Volltextzugriff (PDF)

Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency

Cancer chemotherapy and pharmacology, 2016-07, Vol.78 (1), p.151-156

2016

Volltextzugriff (PDF)

Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials

Drugs (New York, N.Y.), 2009-10, Vol.69 (14), p.1911-1934

2009

Volltextzugriff (PDF)

Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity

Cancer research (Chicago, Ill.), 2013-03, Vol.73 (6), p.1958-1968

2013

Volltextzugriff (PDF)

Gene‐Specific Variant Classifier (DPYD‐Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase

Clinical pharmacology and therapeutics, 2018-10, Vol.104 (4), p.709-718

2018

Volltextzugriff (PDF)

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

Clinical pharmacology and therapeutics, 2019-03, Vol.105 (3), p.598-613

2019

Volltextzugriff (PDF)

A phosphotyrosine switch regulates organic cation transporters

Nature communications, 2016-03, Vol.7 (1), p.10880-10880, Article 10880

2016

Volltextzugriff (PDF)

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)

JNCI : Journal of the National Cancer Institute, 2014-12, Vol.106 (12), p.1

2014

Volltextzugriff (PDF)

microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites

Molecular cancer therapeutics, 2014-03, Vol.13 (3), p.742-751

2014

Volltextzugriff (PDF)

T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0–1M0 non-small-cell lung cancer

European journal of cardio-thoracic surgery, 2019-04, Vol.55 (4), p.682-690

2019

Volltextzugriff (PDF)

Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity

British journal of clinical pharmacology, 2021-08, Vol.87 (8), p.3234-3243

2021

Volltextzugriff (PDF)

Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1277-1285

2019

Volltextzugriff (PDF)

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ( DPYD )

eLife, 2024-04, Vol.13

2024

Volltextzugriff (PDF)

DPYD Testing: Time to Put Patient Safety First

Journal of clinical oncology, 2023-05, Vol.41 (15), p.2701-2705

2023

Volltextzugriff (PDF)

Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies?

Journal of clinical oncology, 2016-01, Vol.34 (3), p.205-207

2016

Volltextzugriff (PDF)

Adverse Prognostic Impact of Intratumor Heterogeneous HER2 Gene Amplification in Patients With Esophageal Adenocarcinoma

Journal of clinical oncology, 2012-11, Vol.30 (32), p.3932-3938

2012

Volltextzugriff (PDF)

Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with Caucasians

Clinical cancer research, 2006-09, Vol.12 (18), p.5491-5495

2006

Volltextzugriff (PDF)

Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter

Cancer research (Chicago, Ill.), 2016-11, Vol.76 (21), p.6362-6373

2016

Volltextzugriff (PDF)

Prognostic Impact of Body Mass Index Stratified by Smoking Status in Patients With Esophageal Adenocarcinoma

Journal of clinical oncology, 2011-12, Vol.29 (34), p.4561-4567

2011

Volltextzugriff (PDF)

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy

Clinical cancer research, 2015-05, Vol.21 (9), p.2038-2044

2015

Volltextzugriff (PDF)

A DPYD Variant (Y186C) Specific to Individuals of African Descent in a Patient With Life-Threatening 5-FU Toxic Effects: Potential for an Individualized Medicine Approach

Mayo Clinic proceedings, 2014, Vol.89 (1), p.131-136

2014

Volltextzugriff (PDF)

1 – 25 von 286

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(260)

Publikationsform

Artikel
(281)
Buchkapitel
(2)
Reviews
(2)
Texte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(194)
Life Sciences & Biomedicine
(190)
Humans
(176)
Oncology
(102)
Biological And Medical Sciences
(97)
Medical Sciences
(89)
Male
(86)
Female
(81)
Pharmacology. Drug Treatments
(70)
Middle Aged
(61)
Aged
(56)
Pharmacology & Pharmacy
(53)
Animals
(49)
Adult
(47)
Antineoplastic Agents
(47)
Dihydrouracil Dehydrogenase
(41)
Dihydrouracil Dehydrogenase - Genetics
(36)
Fluorouracil - Adverse Effects
(35)
Chemotherapy
(31)
Fluorouracil - Metabolism
(30)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Pharmacogenomic‐Guided Therapy in Colorectal Cancer

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy

Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity

Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency

Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials

Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity

Gene‐Specific Variant Classifier (DPYD‐Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

A phosphotyrosine switch regulates organic cation transporters

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)

microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites

T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0–1M0 non-small-cell lung cancer

Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity

Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ( DPYD )

DPYD Testing: Time to Put Patient Safety First

Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies?

Adverse Prognostic Impact of Intratumor Heterogeneous HER2 Gene Amplification in Patients With Esophageal Adenocarcinoma

Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with Caucasians

Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter

Prognostic Impact of Body Mass Index Stratified by Smoking Status in Patients With Esophageal Adenocarcinoma

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis

A DPYD Variant (Y186C) Specific to Individuals of African Descent in a Patient With Life-Threatening 5-FU Toxic Effects: Potential for an Individualized Medicine Approach

Suchergebnisse filtern